Diabetes complications

Temporal trends in treatment-requiring microvascular complications in young-onset diabetes: A nationwide population-based study

Diabetes Res Clin PractPublished Nationwide population-based cohort study

Authors' conclusion

Treatment-requiring microvascular complications in young-onset diabetes declined in Korea, but persistent age- and socioeconomic-related disparities highlight the need for equitable prevention and management.

Study context

Population
Individuals diagnosed with diabetes before age 30 years, Korean Health Insurance Review and Assessment Service data, 2008–2021
Participants
6,202 vs 77,815
Exposure
T1D vs T2D
  • T1Dn = 6,202
  • T2Dn = 77,815
Outcome
Trends in treatment-requiring microvascular complications (diagnostic codes with relevant prescriptions or procedures): age-standardized incidence and prevalence
Follow-up
2008-2021
Methodological detailsage-standardized incidence and prevalence (Poisson regression), time-dependent Cox models
  • Age-standardized incidence and prevalence (Poisson regression)
  • Time-dependent Cox models

Main finding

As reported in the abstract

Treatment-requiring microvascular complications, incidence and prevalence

T1D incidence declined (per 1,000 persons)

from 32.2 to 12.0

T2D incidence declined steadily

from 31.4 to 12.4

T2D prevalence declined steadily

from 72.6 to 43.1

Observational data: associations, not effects.

Further findings

Risk factors for treatment-requiring microvascular complications

T1D: young adulthood, female sex and hypertension increased risk
T2D: young adulthood, male sex, low socioeconomic status and greater comorbidity burden were key predictors

Original publication

Temporal trends in treatment-requiring microvascular complications in young-onset diabetes: A nationwide population-based study. Diabetes Res Clin Pract. Published 4 June 2026. doi:10.1016/j.diabres.2026.113349

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.